

April 30, 2024

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C-1, G- Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers,
Dalal Street,
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Audited Financial Results of the Company for the financial year ended March 31, 2024.

Kindly take the above on record.

Thanking you,

Yours Sincerely,

For RPG Life Sciences Limited

RAJESH RAMESH SHIRAMBEKAR
Digitally signed by RAJESH RAMESH SHIRAMBEKAR
Date: 2024.04.30 22:25:39 +05'30'

Rajesh Shirambekar
Head – Legal & Company Secretary



Encl.: as above



RPG Life Sciences Achieves Remarkable Growth in FY24: 14% Revenue Increase and 29% PBT Growth Year-on-Year, EBITDA Margin Expands to 23.3%.

Mumbai, 30 April, 2024: RPG Life Sciences Limited has announced its financial results for the fourth quarter and year ended March 31, 2024.

	Y-o-Y Revenue from operations	Y-o-Y PBT
Q4 FY24 Highlights	Rs 126.99 crores – up from Rs 118.49 crores	Rs 17.74 crores – up from Rs 13.81 crores
Full year FY24 Highlights	Rs 582.05 crores – up from Rs 512.81 crores	Rs 117.84 crores – up from Rs 91.68 crores

RPG Life Sciences, a part of RPG Group, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 28% Y-o-Y for Q4 FY24, maintaining the upward trajectory in EBITDA margins, which improved to 17.6% from 15.0% Y-o-Y. Revenue from operations of Rs 126.99 crores registered a 7% Y-o-Y growth for Q4 FY24, demonstrating continued robust in-market growth significantly higher than the market.

For the full fiscal year FY24 too, the company achieved a 29% year-on-year increase in PBT and saw an expansion of EBITDA margin from 21.0% to 23.3% year-on-year. Revenue from operations, totaling Rs 582.05 crores, experienced a 14% Y-O-Y growth for FY24.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q4 FY24, the overall performance of the Company continued to be strong. Revenue and PBT grew by 7% and 28% respectively Y-o-Y. The EBITDA margin retained its 5-year long upward trajectory growing from 21.0% to 23.3% Y-o-Y. The Company continues to remain debt-free.

We are well on course in executing all the tenets of our distinctive and smart transformation agenda to achieve our strategic goal of consistent, healthy, and profitable growth. Our top priority, Domestic Formulations, the biggest contributor to the Company’s business, recorded robust growth in both value and volume - significantly and consistently ahead of the market based on its 5 pillar-growth strategy. The comprehensive smart life cycle management program is shaping some of our ‘textbook’ legacy brands into mega brands and our niche specialty portfolio into mega portfolio. New launches in specialty and chronic therapies are helping us shape our Specialty business. We are now working on replicating our smart and successful Rheumatology portfolio entry strategy to enter other specialties like Gastro and Derma to emerge as future growth drivers of Domestic Formulations business. Our MABs portfolio continues to post robust performance. Salesforce productivity continues to register healthy upward momentum, assisted by smart deployment of digital.

We are now shaping our International Formulations and API business basis their own 5 pillars, the key being plants modernization cum capacity expansion by infusion of capex and building a smart product pipeline to become strong future growth drivers. The International Formulations business has been registering healthy double-digit growth. Modernization of our API Plant and building product pipeline, both currently underway, will make API also our third engine of growth.

Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain 5-year uninterrupted Y-o-Y margin expansion trajectory for the past 5 consecutive years.”

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Group (www.rpggroup.com):

RPG Group, established in 1979, is one of India’s fastest growing business groups with a turnover of US\$ 4.4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact:

Priya Singh – 81690 22988 | priya@rpg.in



An  **RPG** Company